Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2016 Jun 21;11(6):e0157508. doi: 10.1371/journal.pone.0157508

Protection of the Transplant Kidney from Preservation Injury by Inhibition of Matrix Metalloproteinases

Michael A J Moser 1,*, Steve Arcand 2, Han-Bin Lin 2,3, Chris Wojnarowicz 4, Jolanta Sawicka 2, Tamalina Banerjee 5, Yigang Luo 1, Gavin R Beck 1, Patrick P Luke 6, Grzegorz Sawicki 2,7,*
Editor: Qing-Xiang Amy Sang8
PMCID: PMC4915675  PMID: 27327879

Abstract

Background

Matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, play an important role in ischemic injury to the heart, yet it is not known if these MMPs are involved in the injury that occurs to the transplant kidney. We therefore studied the pharmacologic protection of transplant kidneys during machine cold perfusion.

Methods

Human kidney perfusates were analyzed for the presence of injury markers such as cytochrome c oxidase, lactate dehydrogenase, and neutrophil-gelatinase associated lipocalin (NGAL), and MMP-2 and MMP-9 were measured. The effects of MMP inhibitors MMP-2 siRNA and doxycycline were studied in an animal model of donation after circulatory determination of death (DCDD).

Results

Markers of injury were present in all analyzed perfusates, with higher levels seen in perfusates from human kidneys donated after controlled DCDD compared to brain death and in perfusate from kidneys with delayed graft function. When rat kidneys were perfused at 4°C for 22 hours with the addition of MMP inhibitors, this resulted in markedly reduced levels of MMP-2, MMP-9 and analyzed injury markers.

Conclusions

Based on our study, MMPs are involved in preservation injury and the supplementation of preservation solution with MMP inhibitors is a potential novel strategy in protecting the transplant kidney from preservation injury.

Introduction

In an effort to increase the number of kidneys available for transplantation in the face of ongoing donor organ shortage, the use of kidneys from more marginal donors has been increasing. This includes the use of kidneys from older donors and those with hypertension [Expanded Criteria Donors (ECD)] as well as Donation after Circulatory Determination of Death donors (DCDD). Unfortunately, both ECD and DCDD donated kidneys are associated with a higher rate of Delayed Graft Function (DGF) and poorer function at one year [1]. Although DCDD donation has increased the numbers of donor kidneys as much as 30% in some programs, this comes with a disadvantage- delayed graft function, poorer long-term function, and increased risk of rejection compared to donation after brain death donation [2,3]. Efforts to minimize the warm ischemic damage and preserve glomeruli would be very worthwhile, especially when one considers that with time, there is steady drop off of glomeruli and kidney transplants have a median graft survival of about 10 years.

Machine cold perfusion of transplant kidneys has shown benefit in terms of both early function and long term function [4,5,6] and this benefit may be greater in more marginal kidneys and those obtained from donation after cardiac death donors [7]. Our group’s previous studies on the heart have shown that MMP-2 is released [8] and also contributes to the injury that occurs to the ischemic heart [9]. Furthermore, the use of MMP inhibitors in hearts subjected to ischemic injury protects the heart from damage [10,11].

MMP-2 and MMP-9 have been shown to be involved in acute and chronic renal injury along the spectrum of basement membrane damage, to tubular atrophy, to fibrosis, to outright renal failure [12,13]. MMPs have also been shown to play an important role in injury to the transplanted kidney. MMP’s are increased in patients with chronic antibody mediated rejection and because of the role of MMPs in the fibrotic renal diseases, MMPs have been suggested as a possible common pathway for chronic allograft nephropathy in the transplanted kidney [14].

Finally, MMP-2 has been shown to be involved in renal ischemia-reperfusion injury in an animal model whereby warm ischemia was induced in situ for 30 to 120 minutes in an MMP-2 deficient transgenic mouse model [15]. The degree of acute tubular injury, necrosis, apoptosis and renal dysfunction was markedly less in the MMP-2 deficient transgenic mice compared to that seen in the wild type mice. Similar mechanisms of injury may be at work in the ischemic cold-perfused kidney, and if this is the case, MMPs should be a clinically useful target for pharmacologic protection of the transplant kidney from preservation injury.

In this study, we examined the perfusate from human perfused kidneys and documented the presence of MMPs. We then developed an experimental animal model of machine cold perfusion to study the effect of inhibition of MMPs.

Results

Release of injury markers from human kidneys during preservation

Twenty-four perfusates of human transplant kidneys obtained from two transplant programs between July 1, 2012 and June 30, 2013 were studied (Table 1). NGAL, LDH and CcO (markers of kidney injury) [16,17,18] activity was detected in all collected samples. The levels of total protein, NGAL and LDH in perfusates from cDCDD kidneys were significantly higher than that found in perfusates from DBD kidneys (Fig 1A, 1B and 1D). In contrast the activity of CcO (Fig 1C), a marker of mitochondrial injury, was similar for the two groups in spite of the shorter preservation time for cDCDD kidneys (11.6 h vs. 17.3 h). Since CcO in the perfusate increases with time in our animal studies, we suspect that CcO in perfusate from cDCDD kidneys would be markedly higher than that for DBD if cDCDD kidneys were preserved for equivalent amounts of time.

Table 1. Demographic information for 24 perfusates obtained from perfusion of human kidneys destined for transplantation.

Donation after Brain Death (DBD)(n = 15) Donation after Circulatory Death (cDCDD)(n = 9) p-value
Donor age (yr (95% CI)) 50.8 (43.1,58.5) 40.0 (32.1,47.9) 0.08
Donor gender (M:F) 4:11 7:2 0.04*
Kidney side (R:L) 10:5 5:4 0.91
Hours on machine cold perfusion (95%CI) 15.9 (13.1,18.8) 10.3 (7.9,12.9) 0.02*
Cold Ischemic Time (CIT) 17.3 (14.2,20.4) 11.6 (9.0,14.2) 0.02*
Delayed Graft Function (DGF) 1/15 (7%) 4/9 (45%) 0.03#
Slow Graft Function (SGF) 1/15 (7%) 8/9 (89%) 0.01
Primary Non Function (PNF) 0 0
Open in a new tab

CI = 95% Confidence Interval.

* calculated using two sided t-test.

# calculated using chi-squared test.

Fig 1. Comparison of injury markers and total protein in perfusate from DBD (n = 17) versus cDCDD (n = 9) human donors.

Fig 1

Open in a new tab

A: NGAL activity B: LDH activity C: Cytochrome c oxidase activity D: Total protein level Error bars represent Standard Error of the Mean (SEM). * p<0.05 using Student’s T test. DBD = Donation after Brain Death cDCDD = controlled Donation after Circulatory Determination of Death LDH = lactate dehydrogenase NGAL = neutrophil gelatinase associated lipocalin

MMPs in perfusates

Analysis for gelatinolytic activity (zymography) showed that all perfusates containedMMP-2 and MMP-9 (molecular weights of 72 and 92 kDa respectively) (Fig 2). The levels of both MMPs were significantly higher in perfusates from cDCDD donors than from DBD donors (Fig 2).

Fig 2. Comparison of MMP-9 and MMP-2 levels in perfusates from kidneys from DBD (n = 15) and cDCDD (n = 9) human donors.

Fig 2

Open in a new tab

Error bars represent Standard Error of the Mean (SEM). * p<0.05 using Student’s T test. DBD = Donation after Brain Death cDCDD = controlled Donation after Circulatory Determination of Death MMP = matrix metalloproteinase.

DGF and MMP levels

Delayed graft function (DGF) was associated with significantly increased MMP-9 and MMP-2 levels (Fig 3A and 3B). In contrast to MMP activities the levels of NGAL and LDH (markers of kidney injury) were not significantly different in both analyzed groups (Fig 3C and 3D).

Fig 3. Matrix Metalloproteinase levels and injury markers in perfusate from clinically transplanted kidneys with DGF (n = 5) and without DGF (n = 19).

Fig 3

Open in a new tab

A: MMP-9 level B: MMP-2 level C: NGAL levelD: LDH activity Error bars represent Standard Error of the Mean (SEM). * p<0.05 using Student’s T test. DGF = Delayed Graft Function MMP = matrix metalloproteinase NGAL = neutrophil gelatinase associated lipocalin.

Microscopic evaluation of animal model of cold perfusion

Rat kidneys (n = 5 per time point) demonstrated preservation of gross architecture under light microscopy in kidneys cold perfused for 22 hours versus those who were flushed and fixed immediately (Fig 4).

Fig 4. Light microscopy (H&E stain) of representative rat kidney at initial flush and after 22 hours of machine cold perfusion (n = 5 per time point).

Fig 4

Open in a new tab

NGAL, LDH and CcO in perfusate from machine cold perfused rat kidneys

Similar to what was observed in human kidney perfusion, NGAL, LDH and CcO were observed in the perfusate from machine cold perfusion preserved rat kidneys (Fig 5A and 5B). The release of analyzed markers was positively correlated with the increasing time of cold perfusion (Fig 5A, 5B and 5C). After 22 h of kidney perfusion the level of NGAL was approximately 10 fold higher than after 5 h of perfusion (Fig 5A). LDH activity and CcO levels were increased also but to a lesser degree (Fig 5B and 5C).

Fig 5. Injury markers in the perfusate of rat kidney with warm ischemic injury undergoing machine cold perfusion at 5, 10, and 22 hours (n = 4–7 each).

Fig 5

Open in a new tab

A: NGAL levelB:LDH activityC: Cytochrome c oxidase activity Error bars represent Standard Error of the Mean (SEM). * p<0.05 using Student’s T test. LDH = lactate dehydrogenase NGAL = neutrophil gelatinase associated lipocalin.

Release of MMPs during cold perfusion

Analysis of perfusates for MMP-9 and MMP-2 activities (molecular weight 92 and 72 kDa respectively) showed higher activities after 22 hours of perfusion in comparison to 5 hours of perfusion. Levels of all analyzed parameters were positively correlated with the duration of cold perfusion (Fig 6).

Fig 6. Comparison of MMP-9 and MMP-2 levels at 5, 10, and 22 hours in perfusates from rat kidney with warm ischemic injury undergoing machine cold perfusion (n = 7).

Fig 6

Open in a new tab

Insert: representative zymography with MMP-9 and MMP-2 activitiesError bars represent Standard Error of the Mean (SEM). * p<0.05 compared to 5 hours using Student’s T test.

Evaluation of rat kidney by electron microscopy (EM)

Changes were seen on EM as shown in Fig 7A. After 22 hours, mitochondrial swelling and loss of detail in the inner cristae was seen in all sections. There was swelling and detachment of tubule basolateral membrane connective tissues.

Fig 7. Representative electron micrographs of rat kidneys and comparison of mitochondrial damage at the time of retrieval and after 22 hours of machine cold perfusion. (5K magnification).

Fig 7

Open in a new tab

A: Clear arrows = mitochondrial swelling and loss of detail at 22 hours Dark arrows = swelling and detachment of the tubular endothelium at 22 hours. B (n = 4). Left panel = cytochrome c oxidaseRight panel = percent undamaged outer membrane of mitochondria. Error bars represent Standard Error of the Mean (SEM). * p<0.05 using Student’s T test.

Analysis of activities CcO and mitochondrial outer membrane integrity in kidney tissue after 22 hours of cold perfusion revealed a marked decrease in activity of approximately 60% and 50% in mitochondrial integrity (Fig 7B). These results correlate to the EM appearance where roughly half of the mitochondria were visibly injured (Fig 7A). Note that the tissue levels of CcO are inversely proportional to the perfusate levels of CcO seen in Fig 5.

Selective inhibition of MMP-2 synthesis

Due to the lack of specific and selective inhibitors to MMP-9, only selective inhibition of MMP-2 (by MMP-2 siRNA) could be investigated. The level of MMP-2 (72 kDa form) in perfusate after 22 hours of cold perfusion was approximately 3 fold higher than at the time of the first perfusate sample at 5 hours (Fig 8). In contrast the level of MMP-2 in perfusates from kidneys perfused for 22 hours in the presence of MMP-2 siRNA was similar to the control level (Fig 8). Also noted were lower levels of LDH and CcO in the perfusate at 22 hours with levels similar to those for kidneys perfused for 5 hours (Fig 9A and 9B).

Fig 8. MMP-2 expression in perfusate from rat kidney cold perfused with KPS-1 solution with MMP-2 siRNA added (n = 4).

Fig 8

Open in a new tab

Insert: a representative zymography for MMP-2. Error bars represent Standard Error of the Mean (SEM). * p<0.05 using Student’s T test. MMP = matrix metalloproteinase.

Fig 9. LDH activity and Cytochrome c oxidase level in perfusate of rat kidney with warm ischemic injury at 5, 10, and 22 hours perfused with KPS-1 with scrambled siRNA versus KPS-1 with siRNA 50 nM (n = 4–7 each).

Fig 9

Open in a new tab

A: LDH activity. B: Cytochrome c oxidase level. Error bars represent Standard Error of the Mean (SEM). * p<0.05 compared to 5 hours using Student’s T test. # p<0.05 compared to 22 hours using Student’s T test.

Effect of DOXY on protein release from rat kidney during cold perfusion

In addition to its antibacterial activity, DOXY has also been shown to have inhibitory effect against cardiac MMP-9 and MMP-2 [5,8,11,19].

Analysis of the inhibitory potential of DOXY on kidney MMP-9 (92 kDa) and MMP-2 (72 kDa) showed complete inhibition of the gelatinolytic activity of both enzymes in gel 2 (DOXY) (Fig 10A).

Fig 10. Effect of doxycycline on LDH, cytochrome c oxidase, and total protein release.

Fig 10

Open in a new tab

A: Confirmation of inhibition of MMP-2 and MMP-9 activity by doxycycline using zymography. B: LDH activity in perfusate of rat kidney with warm ischemic injury at 5, 10, and 22 hours perfused with KPS-1 with and without doxycycline (n = 7 each). C: Cytochrome c oxidase level in perfusate of rat kidney with warm ischemic injury at 5, 10, and 22 hours perfused with KPS-1 with and without doxycycline (n = 7 each). D: Total protein release in perfusate of rat kidney with warm ischemic injury at 5, 10, and 22 hours perfused with KPS-1 with and without doxycycline (n = 6 each). Error bars represent Standard Error of the Mean (SEM). * p<0.05 compared to 5 hours using Student’s T test.# p<0.05 compared to 22 hours using Student’s T test.KPS-1 = Kidney Preservation Solution 1MMP = matrix metalloproteinase.

Perfusion of rat kidney with KPS-1 solution containing DOXY showed decreased levels of LDH and CcO in the perfusate and the level of both enzymes after 22 hours of perfusion was similar to the level after 5 hours of perfusion (Fig 10B and 10C). In the case of LDH, a significant protective effect was already observed after 5 hours of perfusion (Fig 10B).

Protein release into the perfusate by the kidney was also inhibited by DOXY and was similar to the control level throughout the duration of the perfusion (Fig 10D).

Effect of MMP inhibition on NGAL level

The levels of NGAL observed after 22 hours of cold perfusion with DOXY or MMP-2 siRNA were markedly less than that found in perfusate without additives at 22 hours (Fig 11).

Fig 11. NGAL in perfusate of rat kidney with warm ischemic injury at 22 hours with KPS-1 and KPS-1 supplemented with doxycycline and MMP-2 siRNA compared to control (5 hours) (n = 4).

Fig 11

Open in a new tab

Error bars represent Standard Error of the Mean (SEM). * p<0.05 compared to 5 hours using Student’s T test.# p<0.05 compared to 22 hours using Student’s T test.KPS-1 = Kidney Preservation Solution 1MMP = matrix metalloproteinaseNGAL = neutrophil gelatinase associated lipocalin.

Effect of MMP inhibition on rat kidney mitochondrial integrity

Because of the changes in mitochondria observed on electron microscopy consistent with the role of mitochondria in injury noted by other groups [20], the percentage integrity of the outer membranes of mitochondria was measured in kidneys perfused with and without inhibitors of MMP. A decreased level of undamaged outer mitochondrial membranes was observed in the kidneys after 22 hours of cold perfusion compared to the control level whereas kidneys perfused with DOXY or MMP-2 siRNA showed significant protection of this membrane (Fig 12).

Fig 12. Level of undamaged mitochondria measured by the levels of cytochrome c oxidase activity in rat kidney tissue after initial flush and following 22 hours of machine cold perfusion with KPS-1, KPS-1 with doxycycline, and KPS-1 with MMP-2 siRNA (n = 4).

Fig 12

Open in a new tab

Error bars represent Standard Error of the Mean (SEM). * p<0.05 compared to 0 hours using Student’s T test.# p<0.05 compared to 22 hours using Student’s T test.KPS-1 = Kidney Preservation Solution 1MMP = matrix metalloproteinase.

Discussion

In both human and animal studies, our data show that proteins are released during cold perfusion, including MMP-2 and MMP-9. Markedly higher levels of total protein, NGAL, and LDH were seen in perfusate from cDCDD, compared to DBD human donor kidneys. This is in spite of a much shorter time for cDCDD donor kidney perfusion versus DBD donor perfusion (10.3 vs. 15.9 hours on average, p = 0.02). CcO was not significantly higher in the cDCDD perfusate, but this may have to do with the fact that the perfusion time was much less for cDCDD kidneys than it was for DBD kidneys. Markedly higher MMP-2 and MMP-9 release into the perfusate was also seen in cDCDD donors compared to DBD donors.

In a small animal model of cold perfusion, we found that inhibition of MMP-2 during perfusion using MMP-2 siRNA led to a decrease in MMP-2 level in perfusate but also a decrease in LDH, NGAL, and CcO release after 22 hours of perfusion to a level similar to that seen at 5 hours. The use of the non-specific MMP inhibitor, DOXY, in the perfusion solution led to even greater decreased levels, suggesting that MMPs other than MMP-2 are also involved in the injury.

In the electron micrographs of rat kidneys with warm ischemic injury and machine cold perfusion, changes were seen in mitochondria (swelling and loss of definition of cristae). This was supported by the CcO in the actual rat kidney tissue at 22 hours and the CcO levels in perfusate that increased with time. Indeed, while MMPs are generally thought of as acting on extracellular matrices, they also have been shown to have intracellular actions as well, including on the mitochondria [21].

Many previous studies have documented the role of MMP’s in ischemic damage in the heart [4,8,9,10,11] and it seems reasonable that similar mechanisms are at work in the kidney. Other groups have studied the perfusate from human kidneys for transplantation, with mixed results [22,23]. Our approach was unique, however, in that we utilized an animal model in conjunction with the clinical study of human kidneys. With the animal model, we could modify the cold perfusion solution, control the cold ischemic time, and work with more homogeneous groups of kidneys compared to the clinical setting.

Based on our study, it is not possible to conclude on the mechanism whereby MMPs led to an increase of injury markers, however we might speculate based on the electron micrograph appearance and what is known about MMPs that the effect of MMPs on extracellular matrices and on mitochondria may be responsible.

Our results suggest that certain pharmaceutical agents such as DOXY added to the machine cold perfusion solution may be helpful in reducing the amount of preservation injury to transplant kidneys. It is important to note that this study addressed preservation injury and not ischemia-reperfusion injury, which will be the topic of future studies.

The fact that a clinically available drug (DOXY) exists that is capable of inhibiting MMP-2 makes it appealing to consider a studying the drug clinically in machine cold perfusion; given that deceased donor kidneys often come in pairs, it is possible to randomize one to the control arm and the other to receive DOXY in the perfusion solution. The paired nature of such a study would allow for a relatively small ‘n’.

A reduction in the injury to cold preserved DCDD kidneys should result in the ability to use some of the marginal donor kidneys that would normally be rejected or discarded. If even 10% of the kidneys normally rejected by a program are able to be used, this will translate into thousands of kidneys worldwide per year, thus releasing thousands of patients from dialysis and shortening wait times significantly.

Although not a main focus of our study, it is interesting that in DGF, the levels of MMP-2 and MMP-9 were approximately double compared to the non-DGF kidneys, while the measured injury markers were not significantly different between the two groups. Given that the mechanism whereby DGF occurs remains elusive, the possibility that MMPs are involved in DGF requires further study [24].

In conclusion, this study suggests that MMP-2 and likely other MMPs play a role in transplant kidney preservation injury, and that some of this injury can be prevented by the addition of doxycycline in the preservation solution.

Materials and Methods

Human perfusates

Retrieved kidneys were connected to the LifePort® Machine Cold Perfuser (Organ Recovery Systems, Itasca) and perfused with Kidney Perfusion Solution-1 (KPS-1) at 3–5°C using the standard LifePort® settings (pressure 30 mmHg). After the kidney perfusion was terminated, 60–80 mL of the solution was collected and stored at -80°C.

Twenty-four samples (15 DBD and 9 cDCDD) of perfusate from human kidneys were analysed. The standard definition of DGF was used: the need for dialysis in the first week post-transplant. Slow Graft Function (SGF) was defined as serum Cr > 265 μmol/L on post-transplant day 5 and no need for dialysis by day 5 [25].

Preparation of protein from perfusates for analysis

Proteins were precipitated with Ceramic Hydroxyapatite beads (CHT, Bio-Rad, Hercules, CA, USA) in 2.5 mM phosphate buffer with pH 7.0. The bounded proteins were released from CHT beads with 0.5 M phosphate buffer with pH 7.0.

Rat kidney model

The experimental protocol for perfusion of rat kidney is shown in Fig 13. Male Sprague-Dawley rats (200–250 grams, Charles River, Burlington) (4–7 rats per group) were anesthetized with isofluorane. The left renal artery was ligated in situ for 10 minutes of warm ischemia, then cannulated and the kidney removed and rapidly cooled to 4°C. The kidney and tubing were connected to the perfusion apparatus and flushed over 60 min with 20 mL of KPS-1 solution which was then discarded. In keeping with the Canadian Council on Animal Care principle of minimizing the numbers of animals used, other organs were removed in some cases for another experiment, after the kidney was removed. The animal was then sacrificed by exsanguination.

Fig 13. Experimental ProtocolKPS-1 = Kidney Perfusion Solution -1 MMP = matrix metalloproteinase.

Fig 13

Open in a new tab

The machine cold perfusion apparatus consisted of a micro-pump (Mini Pulse 3, Gilson) with flow rate of 0.5 mL/min, operating in a 4°C cold room. The KPS-1 solution (20 mL with or without additive) was continuously infused via the renal artery and the effluent passively drained via the renal vein to be recirculated via the pump.

The kidney was perfused for 22 hours; this time was chosen as longer than the usual cDCDD preservation time in order to increase the chances of having significant injury to the rat kidney. Samples of 0.5 mL were collected at 5, 10, and 22 hours and stored at -80°C. At the end of the perfusion, the kidney was stored at -80°C.

Rat kidney tissue studies

For biochemical studies, frozen kidney tissue was homogenized on ice in 150 mM NaCl, 50 mM Tris-HCl (pH 7.4) containing protease inhibitor cocktail and 0.1% Triton X-100. Homogenates were centrifuged at 10,000 g for 10 min, and the supernatant was stored at -80°C until further use.

Measurement of NGAL level

NGAL level was measured using ELISA kit (Abcam, Toronto), and expressed as μg of protein per mL of perfusate.

Measurement of LDH activity

LDH activity was measured by LDH activity assay (Sigma-Aldrich, St. Louis, MO). Enzyme activity is expressed as the amount of NADH generated from the conversion of lactate into pyruvate.

Measurement of CcO activity

CcO activity was measured using activity assay (Sigma-Aldrich, St. Louis, MO).

Measurement of the mitochondrial integrity

CcO is located on the inner mitochondrial membrane [26]. The integrity of the outer mitochondrial membrane was calculated, according to the manufacture’s instruction (Sigma-Aldrich, St. Louis, MO), as the ratio of CcO activity in the presence and absence of n-dodecyl β-D-maltoside (detergent).

Measurement of protein

Protein content of perfusates and the kidney extract in homogenized buffer was measured with the Bradford protein assay (Bio-Rad, Hercules, CA).

Measurement of MMP levels

Gelatin zymography was performed as previously described [11,27]. After electrophoresis, gels were scanned and MMP levels were measured using Quantity One 4.6 software (Bio-Rad, Hercules, CA). Uncropped gels for Figs 2, 6, 8 and 10 are included in S1 Fig.

Light microscopy

Sections (4 μm) of formalin-fixed and paraffin-embedded tissues were stained with Periodic Acid Schiff’s stain [28,29] then reviewed in blinded fashion by both a veterinary and a human renal pathologist.

Electron microscopy

Kidneys (n = 3 each for time zero and time 22 hours) were flushed with glutaraldehyde and 1 mm cubes of tissue were excised from the upper pole in each kidney for electron microscopy, post fixed in osmium tetroxide, dehydrated in graded ethanol, and embedded in an epoxy resin. Ultrathin sections were cut and stained with uranyl acetate and lead citrate and random areas photographed using digital transmission electron microscopy (Hitachi H9500, Tokyo). These were reviewed in blinded fashion by a renal pathologist.

Inhibition of MMP-2 with DOXY

A concentration of DOXY of 100 μM was used in the zymography gels documenting the inhibitory effect of DOXY and this was the dose used in the therapeutic arm of the rat kidney perfusions. This concentration was used in numerous studies in our lab of MMP inhibition in cardiac ischemia and found to be effective [2].

Inhibition of MMP-2 with siRNA

A stock solution of a mixture containing a pool of 3 target-specific 19–25 nucleotide small interfering RNAs designed to knock down rat MMP-2 gene expression (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used (10 μM concentration in a buffer containing 10 μM Tris-HCl, 20 mM NaCl, and 1 mM EDTA at pH 8.0). As a control, scrambled siRNA (Santa Cruz Biotechnology, Santa Cruz, CA) was used.

Perfusion of rat kidney was with 20 ml of KPS-1 containing MMP-2 siRNA or scrambled siRNA at concentration of 50 nM. The kidney was perfused for 22 hours and perfusate samples were collected as described above.

Statistics

Student’s t test or Chi-squared tests were used as appropriate.

Study approval

This study conforms to the Guide to the Care and Use of Experimental Animals of the Canadian Council on Animal Care. The protocol was approved by the Animal Care and Use Committee of the University of Saskatchewan (certificate # 20130073). All animal surgery was performed under isofluorane anesthesia, and all efforts were made to minimize suffering.

The protocols involving human perfusates were approved by the University of Saskatchewan Biomedical Research Ethics Board (Bio # 12–44) and the Western University Health Sciences Research Ethics Board (HSREB # 101899). The perfusate that was collected for this study was fluid that is ordinarily discarded and is relevant to neither the donor nor the recipient, so the need for patient consent was waived.

Supporting Information

S1 Fig. Uncropped gels for Figs 2, 6, 8 and 10.

(TIF)

Click here for additional data file. (169.7KB, tif)

Acknowledgments

The authors acknowledge Ms. Karen Slattery for electron microscopy and the transplant teams from the Saskatchewan Transplant Program and the London Health Sciences Centre Transplant Program for their help.

Data Availability

All files are available on Figshare: DOI: 10.6084/m9.figshare.3167014, https://figshare.com/s/d1816c01f51d9975dcf5.

Funding Statement

Support was provided to MM by Royal University Hospital Foundation Grant [http://www.ruhf.org], Saskatchewan Transplant Program Startup Funding [www.saskatoonhealthregion.ca/locations_services/Services/organ-tissue-donation/Pages/Saskatchewan-Transplant-Program.aspx], and Department of Surgery Research Chair Startup Funds [http://medicine.usask.ca/department/clinical/surgery.php#DepartmentofSurgery]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Saidi RF, Elias N, Kawai T, Hertl M, Farell ML, Goes N, et al. Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs. Am J Transplant 2007; 7:2769–74. [DOI] [PubMed] [Google Scholar]
  • 2.Yarlagadda SG, Coca SG, Formica RN, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant 2009; 24:1039–1047. 10.1093/ndt/gfn667 [DOI] [PubMed] [Google Scholar]
  • 3.Layler LK, Srinivas TR, Schold JD. Influence of CIT-induced DGF on kidney transplant outcomes. Am J Transplant 2011; 11:2657–2664. 10.1111/j.1600-6143.2011.03817.x [DOI] [PubMed] [Google Scholar]
  • 4.Lam VWT, Laurence JM, Richardson AJ, Pleass HCC, Allen RDM. Hypothermic machine perfusion in deceased donor kidney transplantation: a systematic review. J Surg Res 2013; 180: 176–82. 10.1016/j.jss.2012.10.055 [DOI] [PubMed] [Google Scholar]
  • 5.Cannon RM, Brock GN, Garrison RN, Smith JW, Marvin MR, Franklin GA. To pump or not to pump: a comparison of machine perfusion vs cold storage for deceased donor kidney transplantation. J Am Coll Surg 2013; 216:625–34. 10.1016/j.jamcollsurg.2012.12.025 [DOI] [PubMed] [Google Scholar]
  • 6.Moers C, Smits JM, Mathuis M-HJ, Treckmann J, Gelder F, Napieralski BP, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2009; 360: 7–12. 10.1056/NEJMoa0802289 [DOI] [PubMed] [Google Scholar]
  • 7.Gill J, Dong J, Ens M, Landsberg D, Gill JS. Pulsatile perfusion reduces the risk of Delayed Graft Function in deceased donor kidney transplants, irrespective of donor type and cold ischemic time. Transplantation 2014; 97: 668–674. [DOI] [PubMed] [Google Scholar]
  • 8.Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101: 1833–1839. [DOI] [PubMed] [Google Scholar]
  • 9.Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: Rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol. 2007; 47:211–242. [DOI] [PubMed] [Google Scholar]
  • 10.Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JRB, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106: 1543–1549. [DOI] [PubMed] [Google Scholar]
  • 11.Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, et al. Degradation of Myosin Light Chain In Isolated Rat Hearts Subjected To Ischemia–Reperfusion Injury: A New Intracellular Target for Matrix Metalloproteinase-2. Circulation 2005; 112: 544–552. [DOI] [PubMed] [Google Scholar]
  • 12.Zhao H, Dong Y, Tian X, Tan TK, Liu Z, Zhao Y, et al. Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases. World J Nephrol 2013. August; 2(3): 84–9. 10.5527/wjn.v2.i3.84 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Han WK, Walkar SS, Johnson A, Betensky RA, Dent CL, Devarajan P, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008; 73(7): 863–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Yan Q, Sui W, Wang B, Zou H, Zou G, Luo H. Expression of MMP-2 and TIMP-1 in renal tissue of patients with chronic active antibody medicated renal graft rejection. Diagn Path 2012, 7:141–146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kunugi S, Shimizu A, Kuwahara N, Du X, Takahashi M, Terasaki Y, et al. Inhibition of matric metalloproteinases reduces ischemia-reperfusion acute kidney injury. Lab Invest 2011; 91:170–180. 10.1038/labinvest.2010.174 [DOI] [PubMed] [Google Scholar]
  • 16.Funk JA, Schnellmann RG. Persistent disruption of mitochondrial homeostasis after acute kidney injury. Am J Physiol Renal Physiol. 2012;302(7): F853–64. 10.1152/ajprenal.00035.2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Zager RA, Johnson ACM, Hanson SY. Proximal tubular cytochrome c efflux: Determinant, and potential marker, of mitochondrial injury. Kidney Int. 2004; 65, 2123–2134. [DOI] [PubMed] [Google Scholar]
  • 18.Ayoub JD, Kolarova RF, Levine RJ. Circulating levels of cytochrome c after resuscitation from cardiac arrest: a marker of mitochondrial injury and predictor of survival. American Journal of Physiology—Heart and Circulatory Physiology. 2007; 292 (2): H767–H77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Cadete VJJ, Sawicka J, Bekar LK. Sawicki G. Combined subthreshold dose inhibition of myosin light chain phosphorylation and matrix metalloproteinase-2 activity provides cardioprotection from ischemic/reperfusion injury in isolated rat heart. British Journal of Pharmacology, 170:380–90, 2013. 10.1111/bph.12289 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Jassem W, Heaton ND. The role of mitochondria in ischemia / reperfusion injury in organ transplantation. Kidney Int. 2004. August; 66(2): 514–7. [DOI] [PubMed] [Google Scholar]
  • 21.Zhou HZ, Ma X, Gray MO, Zhu BQ, Nguyen AP, Baker AJ, et al. Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophys Res Commun. 2007; 358:189–195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Moers C, Varnav OC, van Heurn E, Jochmans I, Kirste GR, Rahmel A, et al. The value of machine perfusion perfusate biomarkers for predicting kidney transplant outcome. Transplantation 2010; 90: 966–973. [DOI] [PubMed] [Google Scholar]
  • 23.Bhangoo RS, Hall IE, Reese PP, Parikh CR. Deceased-donor kidney perfusate and urine biomarkers for kidney allograft outcomes: a systematic review. Nephrol Dial Transplant 2012; 27: 3305–3314. 10.1093/ndt/gfr806 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Schroppel B, Legndre C. Delayed kidney graft function: from mechanism to translation. Kidney Int 2014; 86(2): 251–8. 10.1038/ki.2014.18 [DOI] [PubMed] [Google Scholar]
  • 25.Humar A, Johnson EM, Payne WD, Wrenshall L, Sutherland DE, Najarian JS, et al. Effect of initial slow graft function on renal allograft rejection and survival. Clin Transplant. 1997; 11(6):623–7. [PubMed] [Google Scholar]
  • 26.Acín-Pérez R, Fernández-Silva P, Peleato ML, Pérez-Martos A, Enriquez JA. Respiratory active mitochondrial supercomplexes. Mol. Cell. 2008; 32: 529–539. 10.1016/j.molcel.2008.10.021 [DOI] [PubMed] [Google Scholar]
  • 27.Cadete VJJ, Arcand SA, Chaharyn BM, Doroszko A, Sawicka J, Mousseau DD, et al. Matrix metalloproteinase-2 (MMP-2) is activated during ischemia/reperfusion in a model of myocardial infarction. Can J Cardiol,2013; 29:1495–503. 10.1016/j.cjca.2013.03.014 [DOI] [PubMed] [Google Scholar]
  • 28.Bancroft JD, Cook HC. Manual of Histologic Techniques and their Diagnostic Application 1st ed. London: Churchill Livingstone; 1994, p. 161–166. [Google Scholar]
  • 29.Sheehan DC, Hrapchak BB. Theory and Practice of Histotechnology 2nd ed. Coumbus OH: Battelle Press; 1987, p.167–168. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Fig. Uncropped gels for Figs 2, 6, 8 and 10.

(TIF)

Click here for additional data file. (169.7KB, tif)

Data Availability Statement

All files are available on Figshare: DOI: 10.6084/m9.figshare.3167014, https://figshare.com/s/d1816c01f51d9975dcf5.

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES